Deal of the Day — limited-time pharmacy picks!
Brcaone 150mg Tablet

Brcaone 150mg Tablet

Prescription requiredRx Required

Salt Composition: Olaparib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

60 Tablets in Bottle

About The Product

Ovarian Cancer, Breast Cancer

Description

Brcaone 150mg tablet Is used in the treatment of breast and ovarian cancer in women. Its salt formation is Olaparib as an active ingredient and belongs to the class of PARP inhibitor.

It work by inhibiting the PARP enzyme, preventing cancer cells from repairing damaged DNA, which leads to their death and help slow the progression of the disease. Doctors do not prescribe this medication to adults under the age of 18.

Doctor's prescription is required while starting or adjusting the dose, as proper guidance is essential to ensure safety and effectiveness of the treatment.

Indication

Breast cancer and ovarian cancer

Common Side Effects

  • Brcaone 150mg tablet also show various side effects which are acute or chronic as well.
  • Some patients may resolve on their own but some need proper medical attention to cure the disease.
  • Visit the doctor if these symptoms may persist or worsen at the time of treatment: ● Muscle cramps ● Confusion, visual disturbances, seizures, and headache ● Breathlessness ● Swelling of feet ● Changes in heartbeat ● High blood pressure ● Pneumonia ● Loss of appetite ● Sensitivity, tingling and burning sensation of the skin ● Nausea, vomiting, and diarrhea ● Mouth ulcers ● Constipation

Dosage And Duration

  • The correct dosage and duration of Brcaone 150mg tablet is recommended by the healthcare professional.
  • Doctors prescribed this medication with or without food based on patient response to the treatment.
  • Do not self administered, follow the recommended dosage as prescribed by the doctor to ensure safe and effective treatment option.

Mechanism Of Action

Brcaone 150mg tablet is a targeted therapy which contains PARP (inhibitor that works by the blocking PARP enzyme to stop cancer cell from repairing their DNA, leading to cell death.

The medication slowly stops the progression of the disease and helps prevent the spread or further growth of cancer in the body.

Safety Advice

Alcohol
Taking Brcaone 150mg tablet with alcohol is may be dangerous to the patient health but consult the doctor before taking the medication.
Driving
Brcaone 150mg tablet may not cause dizziness or sleepiness but patient may still experience some side effects. It is important to monitor the response of medication and report any unusual symptoms to the doctor.
Pregnancy
Brcaone 150mg tablet is not recommended to pregnant and breastfeeding women as it may affect the fetus or newborn. Take guidance from a healthcare expert to ensure safety and precautions.
Kidney
Kidney patients should take precautions while using Brcaone 150mg tablet as dose adjustment and doctor's prescription is much needed.

Reference

• Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P.

(2018). Olaparib for the treatment of breast cancer.

Expert review of anticancer therapy, 18(6), 519-530. • Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M.

W., Friedlander, M., Balmaña, J., ... & Domchek, S. M.

(2015). Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Journal of clinical oncology, 33(3), 244-250. • Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M.

W., Friedlander, M., Balmaña, J., ... & Domchek, S. M.

(2015). Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Journal of clinical oncology, 33(3), 244-250. • Tutt, A., Robson, M., Garber, J. E., Domchek, S.

M., Audeh, M. W., Weitzel, J.

N., ... & Carmichael, J. (2010).

Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244. • Clarke, N.

W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., ... & Saad, F.

(2022). Abiraterone and olaparib for metastatic castration-resistant prostate cancer.

NEJM evidence, 1(9), EVIDoa2200043.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026